Accelerate Diagnostics (AXDX) 8-K/A Results of Operations and Financial Condition

Exhibit 99.1

ACCELERATE DIAGNOSTICS, INC.

CONDENSED CONSOLIDATED

BALANCE SHEETS

Unaudited

(in thousands, except share data)

	March 31,			December 31,
	2024			2023
ASSETS
Current assets:
Cash and cash equivalents	$	14,606		$	12,138
Investments		1,145			1,081
Trade accounts receivable		2,217			2,622
Inventory		3,249			3,310
Prepaid expenses		1,068			380
Purchase obligation put option asset		—			3,419
Other current assets		1,848			1,516
Total current assets		24,133			24,466
Property and equipment, net		3,197			2,389
Finance lease assets, net		1,225			1,518
Operating lease right of use assets, net		957			1,177
Other non-current assets		1,210			1,816
Total assets	$	30,722		$	31,366
LIABILITIES AND STOCKHOLDERS’ DEFICIT
Current liabilities:
Accounts payable	$	5,108		$	4,796
Accrued liabilities		3,351			3,243
Accrued interest		1,014			164
Deferred revenue and income, current		1,272			1,545
Current portion of convertible notes		726			726
Common warrant liability		3,035			—
Finance lease, current		685			583
Operating lease, current		940			977
Total current liabilities		16,131			12,034
Finance lease, non-current		81			262
Operating lease, non-current		328			570
Deferred income, non-current		1,110			1,122
Other non-current liabilities		1,197			1,164
Convertible notes, non-current		37,655			36,102
Total liabilities	$	56,502		$	51,254
Commitments and contingencies
Stockholders’ deficit:
Preferred shares, $0.001 par value;
5,000,000 preferred shares authorized and no shares issued or outstanding as of March 31, 2024 and December 31, 2023		—			—
Common stock, $0.001 par value;
450,000,000 common shares authorized with 21,811,706 shares issued and outstanding on March 31, 2024 and 14,569,500 shares issued and outstanding on December 31, 2023		21			14
Contributed capital		702,971			694,634
Treasury stock		(45,067	)		(45,067	)
Accumulated deficit		(683,087	)		(668,857	)
Accumulated other comprehensive loss		(618	)		(612	)
Total stockholders’ deficit		(25,780	)		(19,888	)
Total liabilities and stockholders’ deficit	$	30,722		$	31,366

ACCELERATE DIAGNOSTICS, INC.

CONDENSED CONSOLIDATED

STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

Unaudited

(in thousands, except per share data)

	Three Months Ended
	March 31,			March 31,
	2024			2023
Net sales	$	2,921		$	2,812
Cost of sales		2,198			1,801
Gross profit		723			1,011
Costs and expenses:
Research and development		5,173			6,968
Sales, general and administrative		5,706			10,105
Total costs and expenses		10,879			17,073
Loss from operations		(10,156	)		(16,062	)
Other income (expense):
Interest expense		(2,450	)		(418	)
Interest expense related party		—			(1,013	)
Loss on fair value instruments		(1,216	)		—
Foreign currency exchange gain		19			233
Interest income		200			420
Other (expense) income, net		(627	)		45
Total other expense, net		(4,074	)		(733	)
Net loss before income taxes		(14,230	)		(16,795	)
Provision for income taxes		—			—
Net loss	$	(14,230	)	$	(16,795	)
Basic and diluted net loss per share	$	(0.74	)	$	(1.71	)
Weighted average shares outstanding		19,216			9,830
Other comprehensive loss:
Net loss	$	(14,230	)	$	(16,795	)
Net unrealized loss on debt securities available-for-sale		—			24
Foreign currency translation adjustment		(6	)		(255	)
Comprehensive loss	$	(14,236	)	$	(17,026	)

ACCELERATE DIAGNOSTICS, INC.

CONDENSED CONSOLIDATED

STATEMENTS OF CASH FLOWS

Unaudited

(in thousands)

	Three Months Ended
	March 31,			March 31,
	2024			2023
Cash flows from operating activities:
Net loss		(14,230	)		(16,795	)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization		858			802
Provision for bad debts		19			—
Equity-based compensation		1,297			555
Amortization of debt discount and issuance costs		1,596			182
Amortization of debt discount related-party		—			572
Loss on disposal of property and equipment		71			11
Unrealized gain on equity investments		(53	)		(50	)
Units offering issuance cost		680			—
Loss on fair value adjustments		1,216			—
(Increase) decrease in assets:
Contributions to deferred compensation plan		(11	)		—
Accounts receivable		386			(11	)
Inventory		(85	)		(140	)
Prepaid expense and other		(448	)		(239	)
Increase (decrease) in liabilities:
Accounts payable		312			(977	)
Accrued liabilities and other		(658	)		1,945
Accrued interest		850			235
Accrued interest due to related-party		—			441
Deferred revenue and income		(285	)		(79	)
Deferred compensation		33			181
Net cash used in operating activities		(8,452	)		(13,367	)
Cash flows from investing activities:
Purchases of equipment		(513	)		(12	)
Maturities of marketable securities		—			8,221
Net cash (used in) provided by investing activities		(513	)		8,209
Cash flows from financing activities:
Proceeds from issuance of Units to related party		2,050			—
Proceeds from issuance of Units		10,232			—
Units offering issuance cost		(764	)		—
Payments on finance leases		(79	)		(77	)
Net cash provided by financing activities		11,439			(77	)
Effect of exchange rate on cash		(6	)		(262	)
(Decrease) increase in cash and cash equivalents		2,468			(5,497	)
Cash and cash equivalents, beginning of period		12,138			34,905
Cash and cash equivalents, end of period	$	14,606		$	29,408

ACCELERATE DIAGNOSTICS, INC.

CONDENSED CONSOLIDATED

STATEMENTS OF CASH FLOWS (CONTINUED)

Unaudited

(in thousands)

	Three Months Ended
	March 31,		March 31,
	2024		2023
Non-cash investing activities:
Net transfer of instruments from inventory to property and equipment	$	127	$	71
Non-cash financing activities:
Net transfer of instruments from inventory to property and equipment	$	43	$	0
Accrued units offering issuance cost	$	473	$	0
Supplemental cash flow information:
Interest paid	$	10	$	0

See accompanying notes to condensed consolidated financial statements.